

NCCP DOSE BANDING TABLES COVID-19

DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT)

Version 1 April 2020

Version	Date	Amendment	Approved By
1	30/04/2020	Version 1	Working Group

Table of Contents

NCCP DOSE BANDING TABLES COVID-19	1
Table of Contents.....	2
Introduction.....	3
DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:.....	4
CARBOPLATIN IV INFUSION	4
CISPLATIN IV INFUSION.....	5
DOCETAXEL IV INFUSION.....	6
40mg/ml GEMCITABINE IV INFUSION	7
38mg/ml GEMCITABINE IV INFUSION	8
OXALIPLATIN IV INFUSION	9
PACLITAXEL IV INFUSION.....	10
DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION	11
MONOCLONALS - BEVACIZUMAB IV INFUSION.....	11
MONOCLONALS – CETUXIMAB IV INFUSION.....	12
MONOCLONALS - TRASTUZUMAB IV INFUSION.....	13

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

Introduction

This document contains an abridged series of NCCP national dose banding tables which have been amended for the COVID-19 situation. The dose bands in these amended tables have been expanded up to a variance of 10% to reduce the number of dose bands available, facilitate optimal use of outsource provider and to minimise wastage.

These amended dose band tables¹ have been agreed with ISMO and IHS. All dose bands contained in these tables are subject to local implementation and as deemed relevant to local practice. Please refer to the NCCP dose banding documentation and full tables for more detail www.hse.ie/nccpdosebanding

Dose bands exceeding the targeted +/-5% variation from prescribed dose are highlighted in yellow in these amended tables.

Review and Feedback

The amended dose band tables are valid for the duration of the COVID-19 situation and will be reviewed and updated as required. Please send any comments to oncologydrugs@cancercontrol.ie

¹ The original dose band tables were developed in line with the NCCP Dose Banding Guidance document recommendations for dose banding calculations and were agreed with ISMO and IHS. www.hse.ie/nccpdosebanding

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:

CARBOPLATIN IV INFUSION (Version 3A COVID-19)

The dose bands used in this table are constructed based on a 10mg/ml concentration of carboplatin.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
57 - 62	60	3.23% (Upr)" , -5.26% (Lwr)	2mg (Upr), -3mg (Lwr)
63 - 69	66	4.35% (Upr)" , -4.76% (Lwr)	3mg (Upr), -3mg (Lwr)
70 - 77	74	3.90% (Upr)" , -5.71% (Lwr)	3mg (Upr), -4mg (Lwr)
78 - 85	82	3.53% (Upr)" , -5.13% (Lwr)	3mg (Upr), -4mg (Lwr)
86 - 95	90	5.26% (Upr)" , -4.65% (Lwr)	5mg (Upr), -4mg (Lwr)
96 - 110	100	9.09% (Upr)" , -4.17% (Lwr)	10mg (Upr), -4mg (Lwr)
111 - 130	120	7.69% (Upr)" , -8.11% (Lwr)	10mg (Upr), -9mg (Lwr)
131 - 150	140	6.67% (Upr)" , -6.87% (Lwr)	10mg (Upr), -9mg (Lwr)
151 - 170	160	5.88% (Upr)" , -5.96% (Lwr)	10mg (Upr), -9mg (Lwr)
171 - 190	180	5.26% (Upr)" , -5.26% (Lwr)	10mg (Upr), -9mg (Lwr)
191 - 220	200	9.09% (Upr)" , -4.71% (Lwr)	20mg (Upr), -9mg (Lwr)
221 - 260	240	7.69% (Upr)" , -8.60% (Lwr)	20mg (Upr), -19mg (Lwr)
261 - 295	280	5.08% (Upr)" , -7.28% (Lwr)	15mg (Upr), -19mg (Lwr)
296 - 325	310	4.62% (Upr)" , -4.73% (Lwr)	15mg (Upr), -14mg (Lwr)
326 - 370	340	8.11% (Upr)" , -4.29% (Lwr)	30mg (Upr), -14mg (Lwr)
371 - 440	400	9.09% (Upr)" , -7.82% (Lwr)	40mg (Upr), -29mg (Lwr)
441 - 520	480	7.69% (Upr)" , -8.84% (Lwr)	40mg (Upr), -39mg (Lwr)
521 - 600	560	6.67% (Upr)" , -7.49% (Lwr)	40mg (Upr), -39mg (Lwr)
601 - 700	650	7.14% (Upr)" , -8.15% (Lwr)	50mg (Upr), -49mg (Lwr)
701 - 850	770	9.41% (Upr)" , -9.84% (Lwr)	80mg (Upr), -69mg (Lwr)
851 - 1020	930	8.82% (Upr)" , -9.28% (Lwr)	90mg (Upr), -79mg (Lwr)
1021 - 1220	1120	8.20% (Upr)" , -9.70% (Lwr)	100mg (Upr), -99mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

CISPLATIN IV INFUSION (Version 1A COVID-19)

The dose bands used in this table are constructed based on a 1mg/ml concentration of cisplatin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
19 - 21	20	4.76% (Upr) ["] , -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
22 - 24	23	4.17% (Upr) ["] , -4.55% (Lwr)	1mg (Upr), -1mg (Lwr)
25 - 27	26	3.70% (Upr) ["] , -4.00% (Lwr)	1mg (Upr), -1mg (Lwr)
28 - 30	29	3.33% (Upr) ["] , -3.57% (Lwr)	1mg (Upr), -1mg (Lwr)
31 - 33	32	3.03% (Upr) ["] , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	35	5.41% (Upr) ["] , -2.94% (Lwr)	2mg (Upr), -1mg (Lwr)
38 - 42	40	4.76% (Upr) ["] , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)
43 - 47	45	4.26% (Upr) ["] , -4.65% (Lwr)	2mg (Upr), -2mg (Lwr)
48 - 52	50	3.85% (Upr) ["] , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)
53 - 57	55	3.51% (Upr) ["] , -3.77% (Lwr)	2mg (Upr), -2mg (Lwr)
58 - 62	60	3.23% (Upr) ["] , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 68	66	2.94% (Upr) ["] , -4.76% (Lwr)	2mg (Upr), -3mg (Lwr)
69 - 76	72	5.26% (Upr) ["] , -4.35% (Lwr)	4mg (Upr), -3mg (Lwr)
77 - 84	80	4.76% (Upr) ["] , -3.90% (Lwr)	4mg (Upr), -3mg (Lwr)
85 - 94	90	4.26% (Upr) ["] , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 110	100	9.09% (Upr) ["] , -5.26% (Lwr)	10mg (Upr), -5mg (Lwr)
111 - 130	120	7.69% (Upr) ["] , -8.11% (Lwr)	10mg (Upr), -9mg (Lwr)
131 - 150	140	6.67% (Upr) ["] , -6.87% (Lwr)	10mg (Upr), -9mg (Lwr)
151 - 170	160	5.88% (Upr) ["] , -5.96% (Lwr)	10mg (Upr), -9mg (Lwr)
171 - 190	180	5.26% (Upr) ["] , -5.26% (Lwr)	10mg (Upr), -9mg (Lwr)
191 - 220	200	9.09% (Upr) ["] , -4.71% (Lwr)	20mg (Upr), -9mg (Lwr)
221 - 260	240	7.69% (Upr) ["] , -8.60% (Lwr)	20mg (Upr), -19mg (Lwr)
261 - 300	280	6.67% (Upr) ["] , -7.28% (Lwr)	20mg (Upr), -19mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

DOCETAXEL IV INFUSION (Version 2A COVID-19)

The dose bands used in this table are constructed based on a 20mg/ml concentration of docetaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
31 - 34	32	5.88% (Upr) ["] , -3.23% (Lwr)	2mg (Upr), -1mg (Lwr)
35 - 38	36	5.26% (Upr) ["] , -2.86% (Lwr)	2mg (Upr), -1mg (Lwr)
39 - 42	40	4.76% (Upr) ["] , -2.56% (Lwr)	2mg (Upr), -1mg (Lwr)
43 - 48	44	8.33% (Upr) ["] , -2.33% (Lwr)	4mg (Upr), -1mg (Lwr)
49 - 56	52	7.14% (Upr) ["] , -6.12% (Lwr)	4mg (Upr), -3mg (Lwr)
57 - 66	60	9.09% (Upr) ["] , -5.26% (Lwr)	6mg (Upr), -3mg (Lwr)
67 - 80	72	10.00% (Upr) ["] , -7.46% (Lwr)	8mg (Upr), -5mg (Lwr)
81 - 96	88	8.33% (Upr) ["] , -8.64% (Lwr)	8mg (Upr), -7mg (Lwr)
97 - 112	104	7.14% (Upr) ["] , -7.22% (Lwr)	8mg (Upr), -7mg (Lwr)
113 - 132	120	9.09% (Upr) ["] , -6.19% (Lwr)	12mg (Upr), -7mg (Lwr)
133 - 156	144	7.69% (Upr) ["] , -8.27% (Lwr)	12mg (Upr), -11mg (Lwr)
157 - 184	168	8.70% (Upr) ["] , -7.01% (Lwr)	16mg (Upr), -11mg (Lwr)
185 - 220	200	9.09% (Upr) ["] , -8.11% (Lwr)	20mg (Upr), -15mg (Lwr)
221 - 260	240	7.69% (Upr) ["] , -8.60% (Lwr)	20mg (Upr), -19mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

40mg/ml GEMCITABINE IV INFUSION (Version 4A COVID-19)

The dose bands used in this table are constructed based on a **40mg/ml** concentration of gemcitabine

This table is the nationally recommended dose band table for gemcitabine. An alternate table is supplied for certain sites who use gemcitabine 38mg/ml and wish to dose band locally using this concentration.

Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.

Dose Range (mg)	Dose Band (mg)	Maximum variation range	Maximum variation range (mg)
541 - 580	560	3.45% (Upr) ["] , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 640	600	6.25% (Upr) ["] , -3.27% (Lwr)	40mg (Upr), -19mg (Lwr)
641 - 720	680	5.56% (Upr) ["] , -6.08% (Lwr)	40mg (Upr), -39mg (Lwr)
721 - 800	760	5.00% (Upr) ["] , -5.41% (Lwr)	40mg (Upr), -39mg (Lwr)
801 - 880	840	4.55% (Upr) ["] , -4.87% (Lwr)	40mg (Upr), -39mg (Lwr)
881 - 960	920	4.17% (Upr) ["] , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1080	1000	7.41% (Upr) ["] , -4.06% (Lwr)	80mg (Upr), -39mg (Lwr)
1081 - 1260	1160	7.94% (Upr) ["] , -7.31% (Lwr)	100mg (Upr), -79mg (Lwr)
1261 - 1460	1360	6.85% (Upr) ["] , -7.85% (Lwr)	100mg (Upr), -99mg (Lwr)
1461 - 1720	1600	6.98% (Upr) ["] , -9.51% (Lwr)	120mg (Upr), -139mg (Lwr)
1721 - 2020	1840	8.91% (Upr) ["] , -6.91% (Lwr)	180mg (Upr), -119mg (Lwr)
2021 - 2400	2200	8.33% (Upr) ["] , -8.86% (Lwr)	200mg (Upr), -179mg (Lwr)
2401 - 2800	2600	7.14% (Upr) ["] , -8.29% (Lwr)	200mg (Upr), -199mg (Lwr)
2801 - 3200	3000	6.25% (Upr) ["] , -7.10% (Lwr)	200mg (Upr), -199mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		

38mg/ml GEMCITABINE IV INFUSION (Version 4A COVID-19)

The dose bands used in this table are constructed based on a 38mg/ml concentration of gemcitabine

This table is **NOT the nationally recommended** dose band table for gemcitabine. The nationally recommended dose band table is supplied for gemcitabine 40mg/ml. This table is supplied as an alternative for those who wish to use gemcitabine 38mg/ml and dose band locally using this concentration.

Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.

Dose Range (mg)	Dose Band (mg)	Maximum variation range	Maximum variation range (mg)
550 - 589	570	3.23% (Upr)", -3.64% (Lwr)	19mg (Upr), -20mg (Lwr)
590 - 646	608	5.88% (Upr)", -3.05% (Lwr)	38mg (Upr), -18mg (Lwr)
647 - 741	684	7.69% (Upr)", -5.72% (Lwr)	57mg (Upr), -37mg (Lwr)
742 - 874	798	8.70% (Upr)", -7.55% (Lwr)	76mg (Upr), -56mg (Lwr)
875 - 1026	950	7.41% (Upr)", -8.57% (Lwr)	76mg (Upr), -75mg (Lwr)
1027 - 1178	1102	6.45% (Upr)", -7.30% (Lwr)	76mg (Upr), -75mg (Lwr)
1179 - 1349	1254	7.04% (Upr)", -6.36% (Lwr)	95mg (Upr), -75mg (Lwr)
1350 - 1596	1444	9.52% (Upr)", -6.96% (Lwr)	152mg (Upr), -94mg (Lwr)
1597 - 1919	1748	8.91% (Upr)", -9.46% (Lwr)	171mg (Upr), -151mg (Lwr)
1920 - 2280	2090	8.33% (Upr)", -8.85% (Lwr)	190mg (Upr), -170mg (Lwr)
2281 - 2660	2470	7.14% (Upr)", -8.29% (Lwr)	190mg (Upr), -189mg (Lwr)
2661 - 3040	2850	6.25% (Upr)", -7.10% (Lwr)	190mg (Upr), -189mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

OXALIPLATIN IV INFUSION (Version 3A COVID 19)

The dose bands used in this table are constructed based on a 5mg/ml concentration of oxaliplatin

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
55 - 65	60	7.69% (Upr) ["] , -9.09% (Lwr)	5mg (Upr), -5mg (Lwr)
66 - 75	70	6.67% (Upr) ["] , -6.06% (Lwr)	5mg (Upr), -4mg (Lwr)
76 - 85	80	5.88% (Upr) ["] , -5.26% (Lwr)	5mg (Upr), -4mg (Lwr)
86 - 95	90	5.26% (Upr) ["] , -4.65% (Lwr)	5mg (Upr), -4mg (Lwr)
96 - 110	100	9.09% (Upr) ["] , -4.17% (Lwr)	10mg (Upr), -4mg (Lwr)
111 - 130	120	7.69% (Upr) ["] , -8.11% (Lwr)	10mg (Upr), -9mg (Lwr)
131 - 150	140	6.67% (Upr) ["] , -6.87% (Lwr)	10mg (Upr), -9mg (Lwr)
151 - 172	160	6.98% (Upr) ["] , -5.96% (Lwr)	12mg (Upr), -9mg (Lwr)
173 - 202	185	8.42% (Upr) ["] , -6.94% (Lwr)	17mg (Upr), -12mg (Lwr)
203 - 240	220	8.33% (Upr) ["] , -8.37% (Lwr)	20mg (Upr), -17mg (Lwr)
241 - 280	260	7.14% (Upr) ["] , -7.88% (Lwr)	20mg (Upr), -19mg (Lwr)
281 - 320	300	6.25% (Upr) ["] , -6.76% (Lwr)	20mg (Upr), -19mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

PACLITAXEL IV INFUSION (Version 2A COVID 19)

The dose bands used in this table are constructed based on a 6mg/ml concentration of paclitaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
55 - 66	60	9.09% (Upr)" , -9.09% (Lwr)	6mg (Upr), -5mg (Lwr)
67 - 78	72	7.69% (Upr)" , -7.46% (Lwr)	6mg (Upr), -5mg (Lwr)
79 - 90	84	6.67% (Upr)" , -6.33% (Lwr)	6mg (Upr), -5mg (Lwr)
91 - 102	96	5.88% (Upr)" , -5.49% (Lwr)	6mg (Upr), -5mg (Lwr)
103 - 114	108	5.26% (Upr)" , -4.85% (Lwr)	6mg (Upr), -5mg (Lwr)
115 - 132	120	9.09% (Upr)" , -4.35% (Lwr)	12mg (Upr), -5mg (Lwr)
133 - 156	144	7.69% (Upr)" , -8.27% (Lwr)	12mg (Upr), -11mg (Lwr)
157 - 180	168	6.67% (Upr)" , -7.01% (Lwr)	12mg (Upr), -11mg (Lwr)
181 - 204	192	5.88% (Upr)" , -6.08% (Lwr)	12mg (Upr), -11mg (Lwr)
205 - 234	216	7.69% (Upr)" , -5.37% (Lwr)	18mg (Upr), -11mg (Lwr)
235 - 272	252	7.35% (Upr)" , -7.23% (Lwr)	20mg (Upr), -17mg (Lwr)
273 - 318	294	7.55% (Upr)" , -7.69% (Lwr)	24mg (Upr), -21mg (Lwr)
319 - 366	342	6.56% (Upr)" , -7.21% (Lwr)	24mg (Upr), -23mg (Lwr)
367 - 414	390	5.80% (Upr)" , -6.27% (Lwr)	24mg (Upr), -23mg (Lwr)
415 - 462	438	5.19% (Upr)" , -5.54% (Lwr)	24mg (Upr), -23mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION

MONOCLONALS - BEVACIZUMAB IV INFUSION (Version 2A COVID-19)

The dose bands used in this table are constructed based on a 25mg/ml concentration of bevacizumab.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 211	200	5.21% (Upr)" , -5.26% (Lwr)	11mg (Upr), -10mg (Lwr)
212 - 236	225	4.66% (Upr)" , -6.13% (Lwr)	11mg (Upr), -13mg (Lwr)
237 - 275	250	9.09% (Upr)" , -5.49% (Lwr)	25mg (Upr), -13mg (Lwr)
276 - 325	300	7.69% (Upr)" , -8.70% (Lwr)	25mg (Upr), -24mg (Lwr)
326 - 375	350	6.67% (Upr)" , -7.36% (Lwr)	25mg (Upr), -24mg (Lwr)
376 - 425	400	5.88% (Upr)" , -6.38% (Lwr)	25mg (Upr), -24mg (Lwr)
426 - 475	450	5.26% (Upr)" , -5.63% (Lwr)	25mg (Upr), -24mg (Lwr)
476 - 550	500	9.09% (Upr)" , -5.04% (Lwr)	50mg (Upr), -24mg (Lwr)
551 - 650	600	7.69% (Upr)" , -8.89% (Lwr)	50mg (Upr), -49mg (Lwr)
651 - 750	700	6.67% (Upr)" , -7.53% (Lwr)	50mg (Upr), -49mg (Lwr)
751 - 850	800	5.88% (Upr)" , -6.52% (Lwr)	50mg (Upr), -49mg (Lwr)
851 - 950	900	5.26% (Upr)" , -5.76% (Lwr)	50mg (Upr), -49mg (Lwr)
951 - 1100	1000	9.09% (Upr)" , -5.15% (Lwr)	100mg (Upr), -49mg (Lwr)
1101 - 1300	1200	7.69% (Upr)" , -8.99% (Lwr)	100mg (Upr), -99mg (Lwr)
1301 - 1500	1400	6.67% (Upr)" , -7.61% (Lwr)	100mg (Upr), -99mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

MONOCLONALS – CETUXIMAB IV INFUSION (Version 2A COVID-19)

The dose bands used in this table are constructed based on a 5mg/ml concentration of cetuximab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
365 - 400	385	3.75% (Upr) ["] , -5.00% (Lwr)	15mg (Upr), -20mg (Lwr)
401 - 460	420	8.70% (Upr) ["] , -4.13% (Lwr)	40mg (Upr), -19mg (Lwr)
461 - 545	500	8.26% (Upr) ["] , -7.16% (Lwr)	45mg (Upr), -39mg (Lwr)
546 - 645	590	8.53% (Upr) ["] , -6.82% (Lwr)	55mg (Upr), -44mg (Lwr)
646 - 765	700	8.50% (Upr) ["] , -7.06% (Lwr)	65mg (Upr), -54mg (Lwr)
766 - 915	830	9.29% (Upr) ["] , -6.99% (Lwr)	85mg (Upr), -64mg (Lwr)
916 - 1099	1000	9.01% (Upr) ["] , -7.64% (Lwr)	99mg (Upr), -84mg (Lwr)
1100 - 1300	1200	7.69% (Upr) ["] , -7.69% (Lwr)	100mg (Upr), -100mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

MONOCLONALS - TRASTUZUMAB IV INFUSION (Version 2A: COVID-19)

The dose bands used in this table are constructed based on a 21mg/ml concentration of trastuzumab

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
96 - 115	105	8.70% (Upr)" , -9.38% (Lwr)	10mg (Upr), -9mg (Lwr)
116 - 136	126	7.35% (Upr)" , -8.62% (Lwr)	10mg (Upr), -10mg (Lwr)
137 - 157	147	6.37% (Upr)" , -7.30% (Lwr)	10mg (Upr), -10mg (Lwr)
158 - 178	168	5.62% (Upr)" , -6.33% (Lwr)	10mg (Upr), -10mg (Lwr)
179 - 199	189	5.03% (Upr)" , -5.59% (Lwr)	10mg (Upr), -10mg (Lwr)
200 - 230	210	8.70% (Upr)" , -5.00% (Lwr)	20mg (Upr), -10mg (Lwr)
231 - 272	252	7.35% (Upr)" , -9.09% (Lwr)	20mg (Upr), -21mg (Lwr)
273 - 314	294	6.37% (Upr)" , -7.69% (Lwr)	20mg (Upr), -21mg (Lwr)
315 - 356	336	5.62% (Upr)" , -6.67% (Lwr)	20mg (Upr), -21mg (Lwr)
357 - 408	378	7.35% (Upr)" , -5.88% (Lwr)	30mg (Upr), -21mg (Lwr)
409 - 461	441	4.34% (Upr)" , -7.82% (Lwr)	20mg (Upr), -32mg (Lwr)
462 - 514	483	6.03% (Upr)" , -4.55% (Lwr)	31mg (Upr), -21mg (Lwr)
515 - 566	546	3.53% (Upr)" , -6.02% (Lwr)	20mg (Upr), -31mg (Lwr)
567 - 618	588	4.85% (Upr)" , -3.70% (Lwr)	30mg (Upr), -21mg (Lwr)
619 - 683	651	4.69% (Upr)" , -5.17% (Lwr)	32mg (Upr), -32mg (Lwr)
684 - 755	714	5.43% (Upr)" , -4.39% (Lwr)	41mg (Upr), -30mg (Lwr)
756 - 839	798	4.89% (Upr)" , -5.56% (Lwr)	41mg (Upr), -42mg (Lwr)
840 - 933	882	5.47% (Upr)" , -5.00% (Lwr)	51mg (Upr), -42mg (Lwr)
934 - 1090	987	9.45% (Upr)" , -5.67% (Lwr)	103mg (Upr), -53mg (Lwr)

Note: This table has been based on the NCCP Dose Banding Tables [Version 4](#)

NCCP Dose Banding Tables COVID-19	Published: 30/04/2020 Review: 30/04/2021	Version: 1
This information is valid only on the day of printing, for any updates please check www.hse.ie/nccpdosebanding		